Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dimitri P Mikhailidis

Showing results (91-100 of 922) with videos related to

Pageof 93
Sort By:
Journal of Diabetes and Its Complications|May 26, 2023
Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and uric acid: More good news!Niki Katsiki, Manfredi Rizzo, Dimitri P Mikhailidis
Clinical Chemistry|February 26, 2003
Gamma-glutamyltransferase and vascular diseaseBrandon Krijgsman, George Hamilton, Dimitri P Mikhailidis
Archives of Medical Science : AMS|September 1, 2020
CETP inhibition in the REVEAL trial: could we aim higher?Amirhossein Sahebkar, Dimitri P Mikhailidis, Maciej Banach
World Journal of Gastroenterology|November 7, 2022
All journals should include a correspondence sectionNikolaos Papanas, Dimitri P Mikhailidis, Debabrata Mukherjee
Expert Opinion on Pharmacotherapy|November 12, 2013
Summarizing the FIELD study: lessons from a 'negative' trialVasilis Tsimihodimos, Dimitri P Mikhailidis, Moses Elisaf
Current Pharmaceutical Design|December 11, 2013
Editorial: Managing the cardiovascular risk associated with the metabolic syndromeGiuseppe Montalto, Manfredi Rizzo, Dimitri P Mikhailidis
Current Pharmaceutical Design|July 12, 2016
Lipids, Statins and Heart Failure: An UpdateNiki Katsiki, Michael Doumas, Dimitri P Mikhailidis
Journal of Diabetes and Its Complications|November 29, 2022
Obesity and nonalcoholic fatty liver disease in type 1 diabetes mellitus patientsEmir Muzurović, Manfredi Rizzo, Dimitri P Mikhailidis
Clinical Nutrition (Edinburgh, Scotland)|September 15, 2020
Adverse impact of egg consumption on fatty liver is partially explained by cardiometabolic risk factors: A population-based studyMohsen Mazidi, Dimitri P Mikhailidis, Maciej Banach
Current Opinion in Lipidology|December 29, 2016
The Heart Outcomes Prevention Evaluation (HOPE)-3 trial: where do we stand?Niki Katsiki, Dimitri P Mikhailidis, Costas Tsioufis
Pageof 93

Showing results (91-100 of 922) with videos related to

Sort By:
Pageof 93
Journal of Diabetes and Its Complications|May 26, 2023
Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and uric acid: More good news!Niki Katsiki, Manfredi Rizzo, Dimitri P Mikhailidis
Clinical Chemistry|February 26, 2003
Gamma-glutamyltransferase and vascular diseaseBrandon Krijgsman, George Hamilton, Dimitri P Mikhailidis
Archives of Medical Science : AMS|September 1, 2020
CETP inhibition in the REVEAL trial: could we aim higher?Amirhossein Sahebkar, Dimitri P Mikhailidis, Maciej Banach
World Journal of Gastroenterology|November 7, 2022
All journals should include a correspondence sectionNikolaos Papanas, Dimitri P Mikhailidis, Debabrata Mukherjee
Expert Opinion on Pharmacotherapy|November 12, 2013
Summarizing the FIELD study: lessons from a 'negative' trialVasilis Tsimihodimos, Dimitri P Mikhailidis, Moses Elisaf
Current Pharmaceutical Design|December 11, 2013
Editorial: Managing the cardiovascular risk associated with the metabolic syndromeGiuseppe Montalto, Manfredi Rizzo, Dimitri P Mikhailidis
Current Pharmaceutical Design|July 12, 2016
Lipids, Statins and Heart Failure: An UpdateNiki Katsiki, Michael Doumas, Dimitri P Mikhailidis
Journal of Diabetes and Its Complications|November 29, 2022
Obesity and nonalcoholic fatty liver disease in type 1 diabetes mellitus patientsEmir Muzurović, Manfredi Rizzo, Dimitri P Mikhailidis
Clinical Nutrition (Edinburgh, Scotland)|September 15, 2020
Adverse impact of egg consumption on fatty liver is partially explained by cardiometabolic risk factors: A population-based studyMohsen Mazidi, Dimitri P Mikhailidis, Maciej Banach
Current Opinion in Lipidology|December 29, 2016
The Heart Outcomes Prevention Evaluation (HOPE)-3 trial: where do we stand?Niki Katsiki, Dimitri P Mikhailidis, Costas Tsioufis
Pageof 93